Welcome to the fourth edition of Jacob Fleming's Life Science Reporter!

In this spring issue you can find exclusive content from our January-March pharma conferences. Spring is the season of rebirth, a great time to make use of fresh energy in the business as well. Let us share with you the essence of these events in the spirit of

I M P R O V E M E N T.

Improve your position and knowledge on the hottest topics in the pharma industry with Life Science Reporter! Interesting case studies, interviews, white papers and reports are all enclosed in order to fill you up with fresh ideas and innovative concepts. As a special feature you can benchmark your peers by video interviews as well related to marketing excellence and generic events.

We will get back to you in early July and inform you about the upcoming hottest issues at our April-June conferences.

I wish you sunny and successful spring season!

Warm regards,

Bernadett Polgár
Editor
lifescience.reporter@jacobfleming.com

Improve your pricing qualities!

Setting the right price and ensuring that the product is adequately reimbursed is vital for a company’s profitability. Leading pharmaceutical companies understand, how to succeed in a regulatory uncertainty, cost – containment efforts and governmental pressure to lower the drugs’ prices. Overcoming pricing & reimbursement hurdles is crucial for achieving a rapid market access. The 3^rd Annual Pharma Pricing (15-16 January 2008 in Rome) conference brought together the Pharma Industry experts to benchmark best practices in health economics, and their experience with benefit evaluations and reference pricing approach.

• Conference Report
• Case study by Fernando Royo, Vice President – General Manager, Genzyme, Spain
• Article by Global Insights

Improve your Marketing Excellence!

Troubled to find the marketing mix that adds genuine value to your product? Challenged to effectively reach your customer groups? Having a hard time keeping up with generic competition? Achieving and maintaining Excellence in Pharma Marketing becomes an increasingly challenging endeavor. Only a finely attuned complex of marketing inputs promises to maximize your product’s ROI and value. The secret of successful marketing mix, effective targeting, preserving competitive advantage – were all covered at the 4^th Annual Achieving Pharma Marketing Excellence – Maximizing Product Value (15-16 January 2008 in Barcelona) conference. Listen to the valuable video interviews and learn from the real life case studies attached!

• Conference Report
• Case study by Bart Vannieuwenhuyse, Executive Director CRM, Janssen-Cilag, Belgium
• Case study by Reinhard Angelmar, Professor of Pharma Marketing, INSEAD, France
• Video interview with Craig DeLarge, Associate Director, eMarketing, Novo Nordisk, USA
• Video Interview with Reinhard Angelmar, Professor of Pharma Marketing, INSEAD, France
• White paper about Managing Social Media Risk
• White paper by DigiRedo

Improve your potential on the generic market!

The generic share of the pharmaceutical market is expected to rise further as more blockbuster treatments lose patent protection. More and more health plans, insurers and large employers are offering consumers financial incentives to accept generic therapies. It is now estimated that the generic drug industry will grow twice as fast as the overall pharmaceutical market – 20% versus 10% per year. All generic companies are operating in increasingly crowded and competitive environments. How to successfully link your marketing and distribution strategies to increase your market share? And what is the potential of emerging markets? – these are only a few of the questions the generic experts answered at the 3^rd Annual Marketing & Sales in Generics ( 17-18 January 2008 in Barcelona) conference.

• Conference Report
• Case study by Nazmul Hassan, CEO, Beximco Pharmaceuticals, Bangladesh
• Case study by Nicolai Dorka about Sandoz, DorkaBrandConsulting, Germany
• Case study by Ewan Livesey, Executive VP of Corporate Development, Glenmark Pharmaceuticals, Europe
• Case study by Theodore Iliopoulus, VP Operations, Polpharma, UK
• Interview with Theodore Iliopoulus, VP Operations, Polpharma, UK
• Video interview with Georg Cubuk, MD, Esparma, Germany
• Video interview with Brian Tempest, Chief Mentor and Executive Vice Chairman, Ranbaxy, India
• Article by Global Insights

Improve your Clinical Trial’s potential!

Do you want to reduce costs and development times for your clinical trials? Are you taking full advantage of the opportunity in CEE & CIS to accelerate recruitment times and reduce time to market? The Optimizing Clinical Trials in CEE & CIS Region (13-14 February 2008 in Vienna) conference provided solutions to these and some of the remaining challenges. Unbiased case studies explored how to optimize partnerships in CEE and proven ways to overcome operational and regulatory hurdles. Enjoy the takeaway of the conference by having a closer look at the materials below!

• Conference Report
• Case study by Heinrich Klech, Senior Area Director, Medical & Regulatory, Eli Lilly & Co. Austria
• Case study by Edibe Taylan, Medical and Public Affairs Director, Sanofi-Aventis, Turkey
• Case study by Alexander Alfimov, Chief Scientific Officer, Novartis, Russia
• Interview with Alexander Alfimov, Chief Scientific Officer, Novartis, Russia
• Conference photos

Improve your legal strategies!

Successful Pharma & Biotech companies understand that the IP and patenting practices are essential in facilitating enhanced market exclusivity and revenue returns. Legal environment, in particular a patent and regulatory uncertainty, is becoming a big challenge for operating globally. With problems with drug registration in the new emerging markets and counterfeit drugs flooding the markets, the industry is doing all the possible legal steps to protect their profits and good name. The Pharma & Biotech IP & Ligitation (21-22 February 2008 in Brussels) brought together the experts to benchmark the best practices in developing, implementing and improving IP, patent & litigation strategies.

• Conference report
• Case study by Inma Estanol, Senior Examiner Pharmacy, European Patent Office, Germany
• Case study by Mary Catherine DiNunzio, Head of Global Patent Alliances
• Interview with Sandeep K. Rathod, Head of Corporate IP & Formulations Department, Matrix Laboratories Limited, India
• Interview with Mary Catherine DiNunzio, Head of Global Patent Alliances and Patent Operations, H. Lundbeck A / S, Denmark
• Interview with Matthew W. Siegal (partner in the Intellectual Property Practice Group of the New York office of Stroock & Stroock & Lavan LLP) and Amy E. Wilson, Ph.D. (a technical consultant and registered patent agent in Stroock’s Intellectual Property Practice Group), USA
• Conference photos